Arcadia Biosciences (RKDA) Accounts Payables (2014 - 2025)

Arcadia Biosciences has reported Accounts Payables for 12 years, with the latest figure at $1.5 million in Q4 2025.

• For the quarter ending Q4 2025, Accounts Payables rose 106.69% year-over-year to $1.5 million; the trailing twelve-month figure through Dec 2025 stood at $1.5 million (up 106.69% YoY), and the FY2025 full-year result was $1.5 million, up 106.69% from the prior year.
• Accounts Payables for Q4 2025 stood at $1.5 million, down from $2.0 million in the prior quarter.
• The five-year high for Accounts Payables was $5.2 million in Q2 2021, with the low at $703000.0 in Q4 2024.
• Historically, Accounts Payables has averaged $2.5 million across 5 years, with a median of $2.3 million in 2023.
• Annual changes were most pronounced in 2022 — Accounts Payables slumped 75.12% — and 2023, when it surged 111.05%.
• Arcadia Biosciences' Accounts Payables stood at $3.6 million in 2021, then tumbled by 75.12% to $905000.0 in 2022, then jumped by 111.05% to $1.9 million in 2023, then tumbled by 63.19% to $703000.0 in 2024, then soared by 106.69% to $1.5 million in 2025.
• The last three Accounts Payables figures came in at $1.5 million (Q4 2025), $2.0 million (Q3 2025), and $1.6 million (Q2 2025), per Business Quant data.